MARCOS A. SOUZA LIMA, M.D.; GEORGE M. MATTHEW, M.D.; BERGON F. BROKAW, M.D.; HUX ROBERT H., M.D.
To the editor: An implantable and percutaneously refillable pump (Infusaid; Infusaid Corp., Norwood, Massachusetts) has been approved recently by the Food and Drug Administration for continuous intravascular drug infusion. Symptomatic gastritis or ulcer have been reported in 16% of patients after pump placement for hepatic-arterial chemotherapy (1). We report the case of a patient with duodenal ulcer with perforation caused by the infusion catheter.
A 78-year-old white man with metastatic liver disease had a pump implanted by standard technique (2) for regional chemotherapy on 4 December 1984. He was hospitalized 5 months later with tarry stools and weakness. The patient
SOUZA LIMA MA, MATTHEW GM, BROKAW BF, ROBERT H. H. Duodenal Perforation by an Infusion Catheter for Hepatic Chemotherapy. Ann Intern Med. 1985;103:472. doi: 10.7326/0003-4819-103-3-472_1
Download citation file:
Published: Ann Intern Med. 1985;103(3):472.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use